Imaging Activated Macrophages in the Lungs

Stopped early · Phase 1

Conditions studied: COPD

In brief

To test whether folate-based positron emission tomography (PET) imaging using 68Ga-EC2115 can differentiate chronic obstructive pulmonary disease (COPD) patients from control subjects and determine whether the PET signal correlates with measurements of inflammation and disease severity.

Key facts

Study ID

NCT03494114

Run by

Vanderbilt University Medical Center

People needed

13

Starts

2018-11-29

Expected to finish

2021-01-13

Last updated by the study team

2021-08-11

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• ≥45 years of age
• Pulmonary function testing done within last 2 years
• For COPD group, forced expiratory volume at one second/forced vital capacity (FEV1/FVC) ratio < 0.7 and FEV1 < 80% predicted.
• For control group, FEV1/FVC ratio > 0.7 and FEV1 > 80% predicted.
• Scheduled to undergo bronchoscopy for diagnostic evaluation of solitary pulmonary nodule (< 3 cm in diameter)

You may not qualify if…

• Inability to provide informed consent
• Pregnant or lactating women. (Serum pregnancy testing will be required for pre-menopausal women within 24 hours of PET scanning)
• Diagnosis of chronic lung disease other than COPD, i.e. - asthma, idiopathic pulmonary fibrosis
• History of diagnosis or treatment of lung cancer

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.